Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,130 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04697446 | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC | unknown | — | 279 | Blueprint Medicines CorporationINDUSTRY | 3 | Aug 10, 2021 | clinicaltrials |
| NCT04998474 | FRAME-001 Personalized Vaccine in NSCLC | unknown | Phase 2 | 15 | Frame Pharmaceuticals B.V.INDUSTRY | 1 | Aug 10, 2021 | clinicaltrials |
| NCT03976804 | Epidemiological Study to Assess the Prevalence of Lung Cancer(PREVALUNG) | unknown | N/A | 500 | Centre Chirurgical Marie LannelongueOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04267575 | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites | unknown | N/A | 20 | Jerome Canady, M.D.OTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04985201 | Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | unknown | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04982549 | A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC | unknown | Phase 2 | 35 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04990063 | Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 20 | suhaichuanOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04988607 | Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC | unknown | Phase 2 | 90 | Guangdong Association of Clinical TrialsOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT03645317 | Avoiding Cardiac Toxicity in Lung Cancer Patients Treated With Curative-intent Radiotherapy(ACCOLADE) | unknown | N/A | 200 | Prof Corinne Faivre-FinnOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04698941 | Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | unknown | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 29, 2021 | clinicaltrials |
| NCT04867564 | Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy | unknown | — | 100 | Military Institute od Medicine National Research InstituteOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT03893461 | Coagulation System In STereotactic Radiotherapy Of NSCLC(CISTRON) | unknown | — | 110 | Odense University HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04872634 | A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment(SNK_ASTER) | unknown | Phase 1 / Phase 2 | 24 | NKMAX Co., Ltd.INDUSTRY | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04970043 | Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment | unknown | N/A | 58 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 21, 2021 | clinicaltrials |
| NCT04970693 | A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression | unknown | Phase 2 | 64 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT02448797 | Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation(EVIDENCE) | unknown | Phase 3 | 320 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04968002 | Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03439215 | PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer(PFROST) | unknown | Phase 2 | 20 | Fondazione Ricerca TraslazionaleOTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT04965831 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2021 | clinicaltrials |
| NCT04962191 | Idylla EGFR Lung Trial | unknown | — | 150 | Anthony MaglioccoINDUSTRY | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03571126 | Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer | unknown | Phase 4 | 156 | Zunyi Medical CollegeOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT04237805 | A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 1 / Phase 2 | 280 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jul 8, 2021 | clinicaltrials |
| NCT02824965 | Pembrolizumab + CVA21 in Advanced NSCLC | unknown | Phase 1 | 11 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04951648 | A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation | unknown | Phase 3 | 220 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04952168 | Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC | unknown | Phase 2 | 26 | Yuan ChenOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04950400 | A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC | unknown | N/A | 60 | Beijing Chest HospitalOTHER | 0 | Jul 6, 2021 | clinicaltrials |
| NCT04942301 | PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy | unknown | Phase 1 | 24 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04945200 | Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer | unknown | — | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04944069 | Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis(ATTRACT) | unknown | N/A | 69 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT04941417 | Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients | unknown | Phase 2 | 60 | Peking Union Medical CollegeOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT01711697 | An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 16 | Emory UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04541251 | Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC | unknown | Phase 2 | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT01500876 | A Feasibility Study Using Four-Dimensional CT Imaging for Primary Lung Cancer | unknown | N/A | 35 | University of LouisvilleOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04932343 | Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor | unknown | — | 20 | Samsung Medical CenterOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT04933175 | Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer | unknown | Phase 2 | 50 | Liu ZhenhuaOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT04929353 | SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS(IRMA) | unknown | N/A | 280 | University Of PerugiaOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT04928755 | Design and Evaluation of a Novel Methodology for SABR for Lung Cancer | unknown | — | 30 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT04270799 | Lung Nodule Imaging Biobank for Radiomics and AI Research(LIBRA) | unknown | — | 1,000 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT03447678 | Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.(PEOPLE) | unknown | Phase 2 | 65 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04918836 | Immunological Markers Predictive of Response and Toxicity to Checkpoint Inhibitors in Non-small Cell Lung Cancer(IMMUNO-PREDICT) | unknown | — | 150 | University Hospital, BrestOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04919616 | An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC) | unknown | Early Phase 1 | 15 | Shanghai OriginCell Therapeutics Co., Ltd.INDUSTRY | 0 | Jun 9, 2021 | clinicaltrials |
| NCT04905550 | Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC | unknown | Phase 2 | 50 | Chongqing University Cancer HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04813068 | Lung Cancer Patients' Attitudes to a Second Course of Radiotherapy | unknown | — | 30 | NHS Greater Glasgow and ClydeOTHER | 1 | May 28, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT04890795 | A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 237 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | May 18, 2021 | clinicaltrials |
| NCT04887545 | Immune- and Microenvironment- Proteogenomics Profiling for Classifying Lung Cancer Patients | unknown | — | 200 | Universidade Nova de LisboaOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04884009 | A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 106 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04828395 | Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer(F&C) | unknown | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Aug 10, 2021source: clinicaltrials